Divi’s Labs Share Price: 49.0% CAGR in 3 Years as the API Major Outpaces Gland Pharma and Sun Pharma
- November 10, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Divi’s Labs Share Price: 49.0% CAGR in 3 Years as the API Major Outpaces Gland Pharma and Sun Pharma
Divi’s Labs previous close Rs 11,565.50. 3-year CAGR 49.0%. Up 3.3x since 9 Nov 2023. ROE 15.32%. Market cap Rs 3,07,147 crore.
Quick Answer
The Divi’s Labs share price closed at Rs 11,565.50 on 9 November 2026, a compounded annual return of 49.0% over three years. That compares with Laurus Labs at 87.9%, Gland Pharma at 27.0% and Sun Pharmaceutical Industries at 17.4%. The company has a market cap of Rs 3,07,147 crore and a P/E of 91.33 against an industry P/E of 40.13.
The Divi’s Labs share price has delivered one of the strongest three-year runs among large Indian pharma names. Divi’s Laboratories, the Hyderabad-based maker of generic active pharmaceutical ingredients and custom synthesis products, has more than tripled investor money while remaining a very large company by market cap.
We compare that record with Laurus Labs, Gland Pharma and Sun Pharmaceutical Industries. The article calculates three-year CAGR for all four and sets the results beside market cap, valuation, return on equity and debt, using prices adjusted for corporate actions.
Click Here – Get Free Investment Predictions
How Much Has the Divi’s Labs Share Price Returned in 3 Years?
The Divi’s Labs stock closed at Rs 3,498.50 on 9 November 2023 and at Rs 11,565.50 on 9 November 2026. Rs 1 lakh invested three years ago would have grown to about Rs 3.31 lakh, which is a CAGR of 49.0%. This is a price return and leaves out dividends.
CAGR condenses a bumpy three-year ride into one yearly number, which is why it is the fairest way to compare companies of different sizes. A stock such as Divi’s Labs can look spectacular on a chart and still have earned a modest yearly return, so the compounded figure keeps the comparison honest.
The Divi’s Labs share price has also benefited from the global shift of ingredient supply chains towards reliable Indian manufacturers, which has supported the order books of large API makers.
Divi’s Labs vs Laurus Labs, Gland Pharma and Sun Pharmaceutical Industries: 3-Year CAGR Compared
The table ranks the companies by three-year CAGR. Prices on 9 November 2023 are adjusted for splits and bonuses, and the latest figures are the previous close on 9 November 2026.
| Company | Close on 9 Nov 2023 | Previous close (9 Nov 2026) | Price multiple | 3-year CAGR |
|---|---|---|---|---|
| Laurus Labs | Rs 369.70 | Rs 2,454.00 | 6.6x | 87.9% |
| Divi’s Laboratories | Rs 3,498.50 | Rs 11,565.50 | 3.3x | 49.0% |
| Gland Pharma | Rs 1,612.65 | Rs 3,302.40 | 2.0x | 27.0% |
| Sun Pharmaceutical Industries | Rs 1,176.20 | Rs 1,904.50 | 1.6x | 17.4% |
The Divi’s Labs stock ranks second of the four at 49.0%. It sits ahead of Gland Pharma (27.0%) and Sun Pharmaceutical Industries (17.4%). The company ahead is Laurus Labs (87.9%). Laurus Labs leads the group on percentage return, with Divi’s in second place, followed by Gland Pharma and Sun Pharma. Divi’s is far bigger than Laurus and Gland by market cap, so its return came on a larger base of capital.
Look at the Divi’s Labs share price alongside the peers as a snapshot of the last three years. It describes what happened, and valuation and earnings will decide what happens next.
Valuation and Quality Compared
| Company | Market cap | P/E | Industry P/E | ROE | Debt to equity |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | Rs 4,57,073 crore | 41.60 | 40.13 | 13.79% | 0.04 |
| Divi’s Laboratories | Rs 3,07,147 crore | 91.33 | 40.13 | 15.32% | 0.00 |
| Laurus Labs | Rs 1,32,376 crore | 99.35 | 40.13 | 22.11% | 0.43 |
| Gland Pharma | Rs 54,476 crore | 44.08 | 40.13 | 11.57% | 0.02 |
By market cap, Sun Pharmaceutical Industries is the largest of the group at Rs 4,57,073 crore, while the Divi’s Labs stock stands at Rs 3,07,147 crore, about 67% of that size. On earnings, Divi’s Labs shares trade at a P/E of 91.33 against an industry P/E of 40.13, a premium of about 128%, which signals that the market expects faster earnings growth. Peer multiples are Laurus Labs at 99.35, Gland Pharma at 44.08 and Sun Pharmaceutical Industries at 41.60.
Return on equity is 15.32% for the Divi’s Labs stock, which ranks second among the four, and debt to equity stands at 0.00. Trailing EPS is Rs 126.68. Pharma companies with strong ingredient franchises often trade at premium multiples, so P/E should be read together with return on equity and the pace of earnings growth.
What Is Driving the Divi’s Labs Stock?
Divi’s Laboratories makes generic active pharmaceutical ingredients, custom synthesis products for global innovators and nutraceutical ingredients. Its customers include large pharma companies around the world.
Custom synthesis work often runs over long periods, because innovators prefer to stay with a supplier that has proven quality and delivery. That can give the business steady repeat demand.
Followers of the Divi’s Labs share price usually track custom synthesis orders, capacity expansion, margins and the product mix between generics and contract work.
How the Established Players Stack Up
Laurus Labs is a Hyderabad-based maker of ingredients and formulations that has been widening into contract development and manufacturing. It compounded at 87.9% a year, on a market cap of Rs 1,32,376 crore and an ROE of 22.11%.
Gland Pharma is a Hyderabad-based injectables specialist that supplies regulated markets. It compounded at 27.0% a year, on a market cap of Rs 54,476 crore and an ROE of 11.57%.
Sun Pharmaceutical Industries is one of the largest pharma companies in India, with a broad generics and specialty portfolio. It compounded at 17.4% a year, on a market cap of Rs 4,57,073 crore and an ROE of 13.79%.
What Should Investors Track Next?
Three things are worth watching on the Divi’s Labs share price. First, the order flow for custom synthesis and new molecules. Second, margins as capacity is added. Third, the progress of new capacity and its contribution to revenue.
At a P/E of 91, expectations are high. Earnings in this space can be uneven, so size any position with that in mind.
Check the Univest Screener for live fundamentals of pharma stocks
How to Compare Pharma Stocks Yourself
You can repeat this exercise for any pair of stocks, including the Divi’s Labs stock against its peers. Note the adjusted closing price on the base date, take the latest close, divide one by the other, raise the result to the power of one third and subtract one. Then place the CAGR next to market cap, P/E against the industry P/E, ROE and debt to equity. Benchmark the result against the Nifty 50 as well, so you know whether the stock beat the broader market.
A stock that scores well on growth but weakly on quality, or the reverse, deserves closer study before it enters a portfolio. When tracking the Divi’s Labs share price, the same four checks give a more complete picture than price alone.
Download the Univest iOS App or Univest Android App to track the Divi’s Labs share price and compare pharma stocks live.
A Large Ingredient Maker With a Debt Free Balance Sheet
The Divi’s Labs share price compounded at 49.0% a year over three years, ahead of Gland Pharma at 27.0% and Sun Pharma at 17.4%, and behind Laurus Labs at 87.9%. It is debt free, with a debt to equity of 0.00.
Laurus brings a faster record from a smaller base, Gland Pharma offers an injectables focus at a lower multiple, and Sun Pharma brings scale and diversification. The choice depends on how much valuation risk you are comfortable with.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the Divi’s Labs share price today?
Ans. Divi’s Laboratories closed at Rs 11,565.50 on 9 November 2026, according to NSE data. It has a market cap of Rs 3,07,147 crore and a P/E of 91.33. Check live quotes before acting, as prices change every trading day.
What is the 3-year CAGR of the Divi’s Labs stock?
Ans. Divi’s Laboratories delivered a price CAGR of 49.0% over three years, moving from Rs 3,498.50 on 9 November 2023 to Rs 11,565.50 on 9 November 2026. The figure excludes dividends and uses adjusted closing prices.
Is Divis Labs better than Laurus Labs?
Ans. The Laurus Labs stock delivered a higher three-year CAGR at 87.9% than Divi’s at 49.0%. Divi’s is far larger by market cap at Rs 3,07,147 crore, while Laurus has the higher ROE at 22.11% against 15.32%. Both trade at premium multiples, so the better choice depends on your view of growth.
What does Divi’s Laboratories do?
Ans. Divi’s Laboratories is a Hyderabad-based pharmaceutical company that makes generic active pharmaceutical ingredients, custom synthesis products and nutraceutical ingredients for global customers.
Is the Divi’s Labs stock debt free?
Ans. The debt to equity ratio of the Divi’s Labs stock is 0.00 and its return on equity is 15.32%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.
Is Divi’s Labs expensive compared with the industry?
Ans. Divi’s Labs trades at a P/E of 91.33 against an industry P/E of 40.13. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.
Which pharma stock gave the highest return in 3 years?
Ans. Among the companies compared here, Laurus Labs delivered the highest three-year CAGR at 87.9%, followed by Divi’s Laboratories at 49.0%. Past returns do not guarantee future performance.
How do I calculate CAGR for a stock?
Ans. Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.